The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday ...
The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker ...
This health news summary spotlights major developments in cancer treatments, regulatory actions on biotechnology, and the ...
Geron's CEO said the company anticipates a peak market potential of $1.2 billion in the US and some key EU countries by 2030. In March, by a 12-to-2 margin, the FDA adcomm panel voted in favor of ...
Current health news includes Pfizer's lung cancer drug Lorbrena potentially hitting $1 billion in sales by 2030, U.S.
On May 31, 2024, Moderna announced that the FDA has approved its respiratory syncytial virus vaccine (“RSV”), mRESVIA (mRNA-1345). The vaccine was designed to protect adults from lower ...
The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus.
A condition that causes excess iron accumulation in the body Hemochromatosis is a medical condition where people have excessive iron in the body. The most common cause is an inherited genetic change, ...
The drug is a potential treatment for biliary atresia in patients who have undergone surgery in which blocked bile ducts are bypassed to restore normal bile flow. The growth was driven by spending on ...